SBHA

CAS No. 38937-66-5

SBHA( Suberohydroxamic acid | Suberoyl bis-hydroxamic acid )

Catalog No. M24349 CAS No. 38937-66-5

SBHA (suberohydroxamic acid) is a Histone deacetylase (HDAC) inhibitor. HDAC is required for transcriptional modulation, cell cycle regulation and development.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG 27 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SBHA
  • Note
    Research use only, not for human use.
  • Brief Description
    SBHA (suberohydroxamic acid) is a Histone deacetylase (HDAC) inhibitor. HDAC is required for transcriptional modulation, cell cycle regulation and development.
  • Description
    SBHA (suberohydroxamic acid) is a Histone deacetylase (HDAC) inhibitor. HDAC is required for transcriptional modulation, cell cycle regulation and development. It is an enzyme that deacetylates lysine residues on the N-terminal of the core histones.
  • In Vitro
    Suberoyl bis-hydroxamic acid (10, 20 or 50 μM; 24 hours) combination with TRAIL improves apoptosis extent, and when TRAIL is combined with 20 μM SBHA (itself causing only 10–15% apoptosis), resulting in 45–50% cell death.Suberoyl bis-hydroxamic acid (20-50 μM; 10-20 hours) alone has little effect on the expression of the proteins Bcl-xL, Mcl-1, and has albeit mildeffect on Bax. When it combines with TRAIL,which increases the ratio of relative protein expression of Bcl-xL and Bax in early periods, while the change in the ratio of Mcl-1 and Bax increases later in MM-BI and Ist-Mes2 cells.Suberoyl bis-hydroxamic acid (30 μM; 6 hours) causes accumulation of acetylated histone H4 in MEL cells. Apoptosis Analysis Cell Line:MM-BI and Ist-Mes2 cells Concentration:10 μM, 20 μM or 50 μM Incubation Time:24 hours Result:Showed a cooperative effect in cell apoptosis.
  • In Vivo
    Suberoyl bis-hydroxamic acid (intraperitoneal injection; 200 mg/kg; every 2 days; 12 days) reveals a marked increase in the active form of Notch1(NICD) with a concomitant decrease in ASCL1. It reduces the MTC tumor growth. Animal Model:Nude mice injected with human MTC cells Dosage:200 mg/kg Administration:Intraperitoneal injection; every 2 days; 12 days Result:Resulted in an average 55% inhibition of tumor growth in SBHA treatment group.
  • Synonyms
    Suberohydroxamic acid | Suberoyl bis-hydroxamic acid
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    HDAC
  • Recptor
    HDAC1| HDAC3
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    38937-66-5
  • Formula Weight
    204.22
  • Molecular Formula
    C8H16N2O4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 49 mg/mL (239.93 mM; Need ultrasonic); H2O : 8.16 mg/mL (40 mM; Need ultrasonic)
  • SMILES
    ONC(CCCCCCC(NO)=O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Richon VM, Emiliani S, Verdin E et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):3003-7.
molnova catalog
related products
  • PCI-34051

    PCI-34051 is a potent and specific HDAC8 inhibitor with IC50 of 10 nM.

  • NVP-BSK805 2HCl

    NVP-BSK805 2HCl(IC50=0.5 nM), a specific and effective ATP-competitive JAK2 inhibitor, is more than 20-fold specificity over JAK1, JAK3 and TYK2.

  • 2-hexyl-4-Pentynoic ...

    2-hexyl-4-Pentynoic Acid, a valproic acid (VPA) derivatives, is a potent and robust HDACs inhibitor with IC50 value of 13 μM.